The FDA approved Sage Therapeutics' Zulresso, the first medication specifically for women with postpartum depression
Postpartum depression is a type of mood disorder that affects some women after childbirth, causing sadness and loss of interest in activities. Symptoms can start during pregnancy, and the condition can interfere with mother-child emotional bonding.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Sage stock rises after FDA approves first postpartum depression treatment Zulresso
Consulte Mais informação »
Trump opens sage grouse habitat to oil and gas drillingThe Interior Department finalized changes to protections for the sage grouse bird, which could open lands in seven Western states to oil and gas drilling
Consulte Mais informação »
Analysis | The Energy 202: Environmentalists rally to #SaveGrouse after Trump makes it easier to drill in habitatAnalysis: Environmentalists rally to SaveGrouse after Trump makes it easier to drill in habitat
Consulte Mais informação »
College cheating scandal brings resignations and questions at elite prep schoolsSome of Southern California's most elite private schools are caught up in the national college admissions cheating scandal, including Sage Hill and Harvard Westlake.
Consulte Mais informação »
Regulators just approved a new depression drug with the potential to be a game-changerUnlike the depression drugs available for decades, neither of the two new drugs is a pill. One is a nasal spray; the latest is an injection made by Sage.
Consulte Mais informação »
Sage stock rises after FDA approves first postpartum depression treatment Zulresso
Consulte Mais informação »
FDA approves first postpartum depression drugThe US Food and Drug Administration announced on Tuesday it has approved the first medication specifically targeted to treat postpartum depression in women. The treatment is administered as a single 60-hour IV drip, and could offer new hope to moms.
Consulte Mais informação »
‘Transformative’: FDA approves first drug for postpartum depressionBrexanolone is not a pill. The drug is delivered intravenously over the course of a 60-hour infusion, meaning it must be administered in a medically supervised setting, such as a skilled facility or a hospital, rather than at patients’ homes.
Consulte Mais informação »